Can EpiSwitch PSE become more than a diagnostic tool in prostate disease management?
Doctors Studio’s ozone pilot shows promising 30-day shifts in prostate biomarkers tracked via EpiSwitch PSE. Could this reshape trial design? Find out.
Fulgent Genetics acquires Bako Diagnostics and StrataDx to expand AI pathology strategy
Fulgent Genetics acquires Bako Diagnostics and StrataDx to scale AI pathology, expand national reach, and advance precision medicine strategy. Read full analysis.
Co-Diagnostics secures Australian patent for Co-Dx PCR platform, marking global IP expansion milestone
Co-Diagnostics, Inc. has received its first international patent for its Co-Dx PCR platform, with the Australian Patent Office granting coverage for the point-of-care molecular diagnostics system, including its PCR Pro instrument and disposable test cups. This development marks a critical step in the U.S.-based company’s international intellectual property strategy as it advances toward global commercialization […]
Can TrilliumBiO and Oncobit make MRD monitoring standard for uveal melanoma in the U.S.?
TrilliumBiO and Oncobit launch a ctDNA-based monitoring platform for uveal melanoma in the U.S. Learn how this could change rare cancer care in 2026.